Look up one drug

Reason for Use code 557 For the treatment of initial episodes of Clostridium difficile infection; mild cases, if no response or intolerance to an adequate trial of oral metronidazole*: *As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018. Notes: - Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea. - Discontinue antibiotics for other indications if possible. - Higher doses of vancomycin have not been shown to be beneficial. - There is no evidence to support combination therapy with metronidazole or fidaxomicin. Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days Maximum funded quantity: 56 capsules Coverage limit: LU Authorization Period: 14 days Reason for Use code 558 For the treatment of initial episodes of Clostridium difficile infection; moderate or severe, uncomplicated cases*: *As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018. Notes: - Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea. - For mild to moderate cases, treatment should only be continued beyond 7 days if diarrhea persists, up to a maximum of 14 days. - Severe, uncomplicated cases should be treated for 10-14 days. There is no evidence to support treatment durations beyond 14 days. - Higher doses of vancomycin have not been shown to be beneficial. - There is no evidence to support combination therapy with metronidazole or fidaxomicin. Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days Maximum funded quantity: 56 capsules Coverage limit: LU Authorization Period: 14 days Reason for Use code 559 For the treatment of recurrent Clostridium difficile infection (CDI), first recurrence, mild to moderate* or severe, uncomplicated* cases: *As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018. Notes: - Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment. - Treatment should only be continued for 14 days. - Higher doses or longer treatment duration with vancomycin have not been shown to be beneficial. - There is no evidence to support combination therapy with metronidazole or fidaxomicin. Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days Maximum funded quantity: 56 capsules Coverage limit: LU Authorization Period: 14 days Reason for Use code 560 For the treatment of recurrent Clostridium difficile infection (CDI), second or subsequent recurrences, mild to moderate* or severe, uncomplicated* cases: *As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018. Notes: - Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment. - There is no evidence to support combination therapy with metronidazole or fidaxomicin. Funded dose: Vancomycin 125mg four times daily for 10-14 days, followed by vancomycin taper. Maximum funded quantity: 114 capsules Coverage limit: LU Authorization Period: 13 Weeks Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Vancomycin Brand(s): Vancocin and other generics (Note that only specific DINs are reimbursed by the EAP) DOSAGE FORM/ STRENGTH: 125 mg capsules, 250 mg capsules (on case-by-case basis only) Effective September 30, 2019, Vancomycin oral tablets for the treatment of Uncomplicated Clostridium difficile infection may be accessed upon meeting Limited Use Criteria on the Ontario Drug Benefit Formulary. Vancomycin Injection to be used as an oral solution for Clostridium Difficile Infection may be accessed through the Telephone Request Service. Case-by-case consideration for requests not meeting the Limited Use criteria (e.g. higher doses, longer durations, tapering regimens exceeding the dosing limits under LU, complicated C.Difficile Infections) may be considered through external review. Please submit requests to EAP providing adequate and relevant clinical detail to support the request. 52 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 52, record 30, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Jamp-Vancomycin · DIN 02407744 Manufacturer: Jamp Pharma Corporation; listing date 2016-12-22 Health Canada: Marketed since 2021-06-17 · brand JAMP VANCOMYCIN · ATC A07AA09 VANCOMYCIN · form Capsule · route Oral · ingredients VANCOMYCIN (VANCOMYCIN HYDROCHLORIDE) 125 MG · company Jamp pharma corporation · schedule Prescription

DIN 02407744: Jamp-Vancomycin Raw flags: sec12=Y, sec3=Y Item: 081228075; group id 53; item number 0110; lccId 00322; manufacturer id JPC Source form: Cap; strength: 125mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $5.1800; ministry $5.1800 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407744 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89245

Interchangeable products

Vancocin · DIN 00800430 · $5.1800

Shortage status: resolved shortage (ended 2022-03-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407744

Shortage record checked 2026-09-13T08:10:21.292534+00:00